Six-person Cornell spinout raises $90M for prostate cancer drugs

A small biotech, armed with technology out of Cornell University and a former Dana-Farber chief at its helm, has raised $90 million for its cancer drugs.

Carlyle Group appears to be narrowing in on Harvey Schwartz as its next CEO

REITs – Office

Here’s how TD Garden’s new naming rights deal stacks up to others

Supreme Court to hear arguments over Sears $10/year lease at Mall of America next week

Closing the gap: The importance of diversity in capital funding (video)

New Floor & Decor big-box store in works in fast-growing Apopka

How will the next home of the FBI be selected? The GSA is out with its list of criteria.

Longmont retail center changes hands for $3.84M

Six-person Cornell spinout raises $90M for prostate cancer drugs

Previous U.S. Bank expands diversity lending program from just-bought MUFG

Next North Carolina maintains top 10 spot in hospital safety rankings

firststargroup

Kotek touts $500M Oregon housing plan at Leadership Summit

Retirement plans see boost as states mandate IRAs and tax credits lower costs

Norton Healthcare data breach affected more than 2 million people

Houston-based cell therapy company FibroBiologics files to go public

Suggested Posts

Downtown Dayton Office Buildings

Strikes Unlimited in Rocklin formally sold to national bowling alley operator Bowlero

Kenny family sells hotel and retail space in Queensbury to Buffalo-area hospitality firm

Waymo signs industrial lease in Phoenix

NYSE warns Overland Park company that it needs to boost stock price or risk delisting

Dallas-based fintech focused on manufactured home lending secures additional growth funding

MENU

FirstStar Group

More Stories

New chefs named for The Catbird Seat

Previous U.S. Bank expands diversity lending program from just-bought MUFG

Next North Carolina maintains top 10 spot in hospital safety rankings

firststargroup

Related Posts

Suggested Posts

MENU

FirstStar Group

More Stories